Sun On Leqselvi US Launch Ahead, MFN Pricing And Pipeline Changes

Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.

Strategy — Sun readies at-risk launch (Shutterstock/AI-generated)

Sun signaled launch action ahead in the US and a change in plan for certain pipeline specialty assets, even as it awaits, like other industry peers, more clarity on details around US President Donald Trump’s “most favored nation” prescription drug pricing plan (see box below).

Key Takeaways

Sun set for action packed FY2026 in US, with Leqselvi debut on cards.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

PTC To Challenge BioMarin In PKU With Oral Sephience

29 Jul 2025

• By Joseph Haas

PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.